Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Gene Expression Sets and Renal Profiling from the Rain (Renal AL Amyloid Involvement and NEOD00) Trial

Cindy Varga, Raymond Comenzo, Agnes Fogo, Samih Nasr, Matthias Kretzler, Viji Nair, Felix Eichinge, Abhijit Naik

Blood (2022) 140 (Supplement 1): 12450–12451.

https://doi.org/10.1182/blood-2022-162914

Published: 2022

Journal Articles

Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Ping Zhou, Mahesh M Mansukhani, Denis Toskic, Stephanie Scalia, Lisa Lee, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo

Blood (2022) 140 (Supplement 1): 10048–10049.

https://doi.org/10.1182/blood-2022-157790

Published: 2022

Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Blood (2022) 140 (Supplement 1): 4393–4395.

https://doi.org/10.1182/blood-2022-160071

Published: 2022

Journal Articles

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Stephanie Scalia, Denis Toskic, Ping Zhou, Mahesh M Mansukhani, Lisa Lee, Sandy W. Wong, Sascha A. Tuchman, James E. Hoffman, Teresa Fogaren, Cindy Varga, Suzanne Lentzsch, Raymond Comenzo

Blood (2022) 140 (Supplement 1): 10120–10121.

https://doi.org/10.1182/blood-2022-162352

Published: 2022

Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani

Blood (2022) 140 (Supplement 1): 4440–4441.

https://doi.org/10.1182/blood-2022-160204

Published: 2022

Journal Articles

Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis

Ping Zhou, MDPhD, Hashim Mann, MD, Xun Ma, DMD, MSc, PhD, Teresa Fogaren, NP, Yifei Zhang, MD, Denis Toskic, BS, Chakra P Chaulagain, MD, Cindy Varga, MDBSc, Raymond L. Comenzo, MD, Amandeep Godara, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142656

Published: 2020

Journal Articles

Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience

Danai Dima, MD, Xiao Hu, MD MPH, Joshua Dower, MD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-139741

Published: 2020

Journal Articles

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

Danai Dima, MD, Xiao Hu, MD MPH, Joshua Dower, MD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139643

Published: 2020

Journal Articles

Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy

Xiao Hu, MD MPH, Cherng-Horng Wu, MD, Janet Cowan, PhD, Raymond L. Comenzo, MD, Cindy Varga, MDBSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139780

Published: 2020

Journal Articles

Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease

Anupama Kumar, MD, David Drew, MD, Leslie Inker, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5498.

https://doi.org/10.1182/blood-2019-127618

Published: 2019

Journal Articles

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Cindy Varga, MD BSc, Viji Nair, PhD, Agnes Fogo, MD, Samih Nasr, MD, Bradley Godfrey, PhD, Felix Eichinge, PhD, Denis Toskic, BS, Matthias Kretzler, MD, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 5500.

https://doi.org/10.1182/blood-2019-123228

Published: 2019

Journal Articles

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

So Yeon Kim, MD, Amanda Vest, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5502.

https://doi.org/10.1182/blood-2019-123890

Published: 2019

Journal Articles

Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia Therapy

Nauman Saleem Siddiqui, MD, Andreas Klein, MD, Amandeep Godara, MD, Cindy Varga, MD BSc, Rachel J. Buchsbaum, MD, Michael C. Hughes, PhD

Blood (2019) 134 (Supplement_1): 3435.

https://doi.org/10.1182/blood-2019-128823

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

Journal Articles

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

Amandeep Godara, MD, Ping Zhou, MD PhD, Benjamin Rosenthal, BS, Adin Kugelmass, BSc, Denis Toskic, BS, Teresa Fogaren, NP, Cindy Varga, MD BSc, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4409.

https://doi.org/10.1182/blood-2019-126988

Published: 2019

Journal Articles

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Shayna Sarosiek, Vaishali Sanchorawala, MD, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 4353.

https://doi.org/10.1182/blood-2019-131863

Published: 2019

Journal Articles

Identifying a Murine Xenograft Model Relevant to Light-Chain Specific Approaches to Human Ig Light-Chain Diseases

Adin Kugelmass, BSc, Ping Zhou, MD PhD, Xun Ma, DMD, MSc, PhD, Denis Toskic, Amandeep Godara, MD, Melissa Warner, BS, Lisa Xingguang Lee, MD, Teresa Fogaren, NP, Cindy Varga, MD BSc, Raymond L Comenzo, MD

Blood (2018) 132 (Supplement 1): 5611.

https://doi.org/10.1182/blood-2018-99-119381

Published: 2018

Journal Articles

Seeking AL Amyloidosis Very Early: The SAVE Trial — Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma

Ping Zhou, MD PhD, Adin Kugelmass, BSc, Denis Toskic, Melissa Warner, BS, Lisa X. Lee, MD, Teresa Fogaren, NP, Cindy Varga, MD BSc, Raymond L Comenzo, MD

Blood (2018) 132 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2018-99-112902

Published: 2018

Journal Articles

Beyond NEOD001 for systemic light-chain amyloidosis

Cindy Varga, Suzanne Lentzsch, Raymond L. Comenzo

Blood (2018) 132 (18): 1992–1993.

https://doi.org/10.1182/blood-2018-07-865857

Published: 2018

Journal Articles

Daratumumab Activity Is Agnostic to Fc Gamma Receptor 3A (FcγR3A) 158 Genotype in Patients with Primary Refractory or Relapsed Systemic AL Amyloidosis

Lisa Xingguang Lee, MD, Katelynn Ho, Ping Zhou, PhD MD, Cindy Varga, MD BSc, Teresa Fogaren, NP, Denis Toskic, Adin Kugelmass, Raymond Comenzo, MD

Blood (2017) 130 (Supplement 1): 3164.

https://doi.org/10.1182/blood.V130.Suppl_1.3164.3164

Published: 2017

NARROW

Gene Expression Sets and Renal Profiling from the Rain (Renal AL Amyloid Involvement and NEOD00) Trial

Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Therapeutic Activity of Combining BCL-2 and HMG-CoA Reductase Inhibition in Systemic Light-Chain Amyloidosis

Pattern of Use and Outcomes of Daratumumab Therapy in Patients with Multiple Myeloma in a Real-World Setting: A Single Institution Experience

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

Outcomes of Patients with Multiple Myeloma Harboring Gain/Amplification 1q in the Era of Modern Therapy

Monoclonal Gammopathies and Their Significance: A Retrospective Analysis of Monoclonal Gammopathy and Renal Disease

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission but with Persistent Renal Disease

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia Therapy

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase Inhibition

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Identifying a Murine Xenograft Model Relevant to Light-Chain Specific Approaches to Human Ig Light-Chain Diseases

Seeking AL Amyloidosis Very Early: The SAVE Trial — Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma

Beyond NEOD001 for systemic light-chain amyloidosis

Daratumumab Activity Is Agnostic to Fc Gamma Receptor 3A (FcγR3A) 158 Genotype in Patients with Primary Refractory or Relapsed Systemic AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only